Hussman Strategic Advisors Inc. Makes New Investment in Haemonetics Corporation $HAE

Hussman Strategic Advisors Inc. acquired a new stake in Haemonetics Corporation (NYSE:HAE) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 10,500 shares of the medical instruments supplier’s stock, valued at approximately $512,000.

Several other institutional investors and hedge funds have also bought and sold shares of HAE. EverSource Wealth Advisors LLC lifted its position in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares in the last quarter. GAMMA Investing LLC increased its holdings in Haemonetics by 59.4% during the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 165 shares in the last quarter. Versant Capital Management Inc raised its stake in shares of Haemonetics by 216.4% in the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 567 shares during the last quarter. Byrne Asset Management LLC bought a new position in shares of Haemonetics in the third quarter valued at approximately $42,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Haemonetics during the second quarter valued at approximately $64,000. 99.67% of the stock is owned by institutional investors.

Haemonetics Stock Performance

NYSE HAE opened at $66.10 on Thursday. The firm has a market cap of $3.09 billion, a P/E ratio of 19.33, a price-to-earnings-growth ratio of 1.41 and a beta of 0.29. The company has a quick ratio of 1.03, a current ratio of 1.64 and a debt-to-equity ratio of 1.08. The company’s 50 day moving average is $78.90 and its 200-day moving average is $65.57. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $87.32.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.15. The company had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The firm’s quarterly revenue was down 5.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Sell-side analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Wall Street Analyst Weigh In

HAE has been the subject of a number of analyst reports. Raymond James Financial reissued an “outperform” rating and issued a $90.00 price target on shares of Haemonetics in a research report on Friday, November 14th. Mizuho increased their target price on shares of Haemonetics from $75.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Robert W. Baird upped their price objective on shares of Haemonetics from $87.00 to $99.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and an average price target of $84.40.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.